Explore our primary export catalog featuring premium grade modified nucleosides, therapeutic peptides, protected amino acids, and high-purity APIs for global distribution.
The rapid advancement of messenger RNA (mRNA) medicine—spanning prophylaxis, oncology vaccines, protein replacement therapies, and CRISPR gene-editing delivery—hinges fundamentally upon chemical nucleotide modifications. Among these, Pseudouridine (Ψ) and its derivative N1-Methylpseudouridine (m1Ψ) stand as the definitive cornerstone of therapeutic transcript stabilization and immunogenicity evasion.
Unmodified single-stranded RNA triggers intracellular pattern recognition receptors (PRRs), notably Endosomal Toll-Like Receptors TLR7 and TLR8, alongside RIG-I and MDA5 pathways. Incorporating high-purity Pseudouridine replaces standard uridine residues, preventing innate immune recognition, mitigating severe cytokine cascades, and prolonging cellular mRNA half-life.
Pseudouridine modification alters the C1'-N1 C-glycosidic bond to a unique C1'-C5 linkage. This structural alteration enhances base-stacking thermodynamics, rigidifies the RNA backbone, and facilitates smoother ribosomal decoding. Translational capacity increases up to 10-fold, maximizing target antigen synthesis per transcribed dose.
During chemical synthesis, structural impurities such as alpha-anomers or residual free uridine can compromise downstream enzymatic In Vitro Transcription (IVT). Gentolex ensures strict chromatographic isolation, producing beta-anomer pure Pseudouridine modified nucleosides with low endotoxins suitable for human formulation.
Gentolex’s goal is to create opportunities connecting the world with better services and guaranteed products. Up to date, Gentolex Group has been serving customers from more than 10 countries, specially, representatives are established in Mexico and South Africa.
Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
An overall factory construction area of 250,000 square meters under international standard to offer flexible, scalable and cost-effective solutions.
Gentolex offers an extensive range of APIs and intermediates for development study and commercial application with cGMP standard. Full documentation supported.
Custom synthesis, analytical validation, batch optimization, and scaled production of rare nucleotide modifications and complex peptide chemistry.
For clients preferring to avoid complex multiple vendor management, we deliver customized procurement with superior global supply chain integration.
Securing a resilient, high-capacity, and cost-predictable supply chain for modified nucleosides is a critical strategic requirement for pharmaceutical procurement officers. Gentolex leverages China’s unparalleled chemical manufacturing cluster advantages to mitigate bottleneck risks.
By producing core starting compounds—such as ribose derivatives and modified pyrimidines—in-house or through closely coupled domestic partners within China, Gentolex shields global customers from upstream monomer scarcity and sharp cost spikes.
Our expansive industrial footprint allows seamless transitions from R&D grams to commercial metric-ton manufacturing. Large batch sizes reduce inter-batch variability, guaranteeing identical chromatographic profiles across long-term supply cycles.
High-efficiency catalytic conversion ensuring >99% regioselectivity and beta-anomeric purity.
Industrial scale liquid chromatography eliminating trace nucleoside degradation fragments.
Low-moisture vacuum drying under ISO 7 cleanroom conditions with full NMR, MS, and HPLC documentation.
Validated temperature-controlled shipping packaging ensuring chemical integrity to any destination.
Whether supplying academic research institutes in North America, biotech hubs in Europe, or commercial CDMOs across Asia-Pacific and Latin America, our Pseudouridine portfolio matches specific operational workflows.
Essential for SARS-CoV-2 boosters, seasonal influenza, and emerging RSV mRNA vaccine formulations. Incorporating modified pseudouridine prevents systemic inflammation upon administration while maximizing protective neutralizing antibody titers.
Personalized cancer vaccines require fast-turnaround IVT reactions. Gentolex supplies pre-validated, ultra-low endotoxin batch lots that integrate seamlessly into automated high-throughput RNA synthesis platforms.
Chemical modification of single guide RNAs (sgRNAs) with modified nucleosides enhances off-target resistance, increases intracellular nuclease stability, and ensures controlled Cas9/Cas12 expression timing.
Under Google E-E-A-T principles and rigorous pharmaceutical audit requirements, product claims must be backed by verifiable testing methodologies and international compliance standards.
Our manufacturing units operate under strict Quality Management Systems (QMS) aligned with US FDA, EMA, and NMPA guidelines for active raw materials.
Every batch is released with a Certificate of Analysis (COA), high-resolution 1H/31P NMR spectra, LC-MS purity trace, residual solvent screening (ICH Q3C), and heavy metal analysis (ICP-MS).
We assist clients with Drug Master File (DMF) registrations, REACH compliance, TSE/BSE-free attestations, and custom regulatory submissions in target export countries.
| Appearance | White to off-white crystalline powder |
| HPLC Purity | ≥ 99.5% |
| Beta-Anomer Ratio | ≥ 99.8% |
| Endotoxin Level | < 0.05 EU/mg (LAL method) |
| Heavy Metals | ≤ 10 ppm total |
| Water Content (KF) | ≤ 1.0% |
As RNA therapeutics mature beyond infectious disease vaccines into systemic therapeutics, the market demands higher efficiency modified monomers.
Studies consistently demonstrate that N1-Methylpseudouridine (m1Ψ) exhibits superior translational capacity and lower immune cytotoxicity compared to unmodified Pseudouridine. Gentolex offers scalable commercial synthesis for both m1Ψ nucleosides and nucleotide triphosphates (m1ΨTP).
Circular RNA constructs lack 5' cap and 3' poly(A) tails, providing exceptional exonuclease resistance. Modified nucleosides are being engineered directly into circRNA enzymatic ligation pathways to reduce internal immune sensing while maintaining prolonged intracellular translation.
saRNA platforms require significantly lower microgram doses. Incorporating high-purity nucleosides ensures high-fidelity replication by viral replicase enzymes without triggering premature interferon response shutdowns.
Browse additional specialized chemical intermediates, research peptides, and key APIs available for global export.
Stay informed with the latest scientific publications, manufacturing updates, and API product releases from Gentolex Group.
Selank Acetate API is a synthetic heptapeptide active pharmaceutical ingredient composed of Thr-Lys-Pro-Arg-Pro-Gly-Pro sequence, developed for advanced neuropharmacological studies...
View Details
As a professional Thymosin Beta-4 API manufacturer and supplier, we provide high-quality Tβ4 peptide API solutions for biotechnology companies and research organizations globally...
View Details
BPC-157 API is a synthetic pentadecapeptide gaining attention in peptide research due to biological activities related to tissue repair, angiogenesis, and inflammatory regulation...
View Details
Semax, a synthetic peptide derived from an ACTH fragment, has attracted major attention among researchers due to its unique neuroprotective and cognitive research applications...
View Details
SS-31 API (Elamipretide, MTP-131) is a synthetic mitochondria-targeting tetrapeptide designed to bind cardiolipin in the inner mitochondrial membrane, stabilizing cellular energetics...
View DetailsEssential technical and procurement insights for purchasing mRNA Pseudouridine and modified nucleosides from Gentolex Group.
